Search

Your search keyword '"Hoos, A."' showing total 4,897 results

Search Constraints

Start Over You searched for: Author "Hoos, A." Remove constraint Author: "Hoos, A."
4,897 results on '"Hoos, A."'

Search Results

451. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates

465. Algorithm Configuration in the Cloud: A Feasibility Study

466. Evaluating Instance Generators by Configuration

467. AClib: A Benchmark Library for Algorithm Configuration

469. VPint: value propagation-based spatial interpolation

471. Automating Data Science.

472. COVERING NEW GROUND.

473. Industrializing engineered autologous T cells as medicines for solid tumours

487. Risk Factors for Enteric Pathogen Exposure among Children in Black Belt Region of Alabama, USA.

488. Introducing the enterprise data marketplace: a platform for democratizing company data.

489. CCR Translation for the Article from Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

490. Supplementary Data from The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

491. Supplementary figure 2 from The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

492. Figure S1 from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

493. Table S1 from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

494. Supplementary figure 1 from The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

495. Supplementary tables S1-S6 from The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

496. Supplementary Figure legends from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

Catalog

Books, media, physical & digital resources